Stifel analyst Paul Matteis raised the firm’s price target on Alnylam (ALNY) to $495 from $441 and keeps a Buy rating on the shares. After an “outstanding first quarter” for Alnylam’s Vutrisiran, which the firm believes is on track to “beat numbers” handily in the near term, the firm is updating its TTR market model, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY: